

Daniel Brook

Partner

London

Biography

Daniel is a patent litigator in the UK. He acts for clients such as MSD, Lilly, Amgen and BMS. Recent key cases include Actavis v Lilly (Supreme Court), Schutz v Werit (Supreme Court), and BMS v Teva (availability of interim injunctions).

He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.

Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars, IAM Patent 1000 and Who's Who Legal.

Representative experience

Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.

Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed (Supreme Court) and gemcitabine.

Acting for BMS in relation to patent challenges around its products, dasatinib, efavirenz and atazanavir.

Acting for a number of electronic clients including HTC, ZTE and BlackBerry on European patent litigation matters.



Phone

+44 20 7296 5484

Fax

+44 20 7296 2001

Email

daniel.brook@hoganlovells.com

Languages

English

Practices

Patents

IP Litigation, Arbitration, and
Alternative Dispute Resolution

Industries

Life Sciences and Health Care
Technology

Areas of focus

IP Rights in Transactions
Medical Devices

Awards and rankings

- Hot 100, *The Lawyer*, 2018
- Intellectual Property: Patent Litigation (UK), *Chambers Global*, 2017-2018
- Impact Case of the Year, *Managing Intellectual Property Awards*, 2018
- Intellectual Property: Patent Litigation, *Chambers UK*, 2014 - 2018
- Pharmaceuticals and biotechnology, *Legal 500*, 2013 - 2018
- Intellectual Property, *Legal 500*, 2013 - 2018
- IAM Patent 1000, 2013 - 2018
- Patents, *IP Star*, 2017 - 2018
- Patents, *Who's Who Legal*, 2018

Latest thinking and events

- News
 - Court of Appeal hands down reasons for awarding AZ an interim injunction in the UK against Glenmark's generic dapagliflozin for type II diabetes
- News
 - UK Court of Appeal grants AstraZeneca an interim injunction against Glenmark's generic dapagliflozin for type II diabetes
- Insights and Analysis
 - Court of Appeal grants Mylan stay of injunction pending appeal against validity of Neurim divisional
- Webinar
 - Select IP with Hogan Lovells | Webinar no. 12: Patent Litigation: Use of experts
- Insights and Analysis
 - Patent Litigation 2021 guide *Chambers and Partners*

Pharmaceuticals and
Biotechnology

Cell, Tissue, and Gene Therapies

Education and admissions

Education

M.A. Natural Sciences -
Chemistry, University of
Cambridge, 1999

M.Sci, University of Cambridge,
1999

Memberships

AIPPI Council Member

CIPA

EPLAW

Accolades

"Daniel Brook is 'technically very competent' and 'gets the ins and outs of even the most complex piece of patent litigation'".

Legal 500, 2018
